Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Trilipix Delayed-Release Capsules, 45 mg and 135 mg, of Abbvie Inc. Fenofibric Acid Delayed-Release Capsules have an estimated market size of $93 million for twelve months ending December 2016, according to IMS.
Fenofibric Acid Delayed- Release Capsules are indicated as an adjunctive therapy to diet to reduce triglycerides (TG) in patients with severe hypertriglyceridemia and to reduce elevated LDL-C, total cholesterol (Total-C), TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia.
Alembic now has a total of 56 ANDA approvals (50 final approvals and 6 tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1783.55 |
| Dr. Reddys Lab | 1277.80 |
| Cipla | 1400.70 |
| Zydus Lifesciences | 1088.90 |
| Lupin | 2268.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: